CLOs on the Move


 
SportsArt is the fitness industry leader in eco-innovation, unique design and green manufacturing excellence; and the only fitness company able to harness human energy and convert it into utility-grade electricity. We`ve built our reputation through rebuilding and sustaining lives in the fitness, medical rehabilitation, performance and wellness markets.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Medical Concepts Development

MCD is a quality, solution oriented manufacturer of adhesive coated films, pouches, tapes, and special purpose products. MCD is ISO 13485:1996 Certified. Operating from it's GMP compliant Woodbury, Minnesota facility, MCD develops, markets, and

Truly Instrument Limited

Truly Instrument Limited is a Alhambra, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bay Shore Medical

Bay Shore Medical is a Ronkonkoma, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

North American Medical Management

For over a decade, NAMM California has championed physician driven medical groups resulting in superior quality health care for patients. North American Medical Management, California (NAMM California) develops and manages medical groups providing a

OXiGENE

OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are potentially complementary with anti-angiogenic drugs and chemotherapeutic agents. OXiGENE has ongoing VDA drug development programs and is committed to advancing the science of VDAs and their potential as innovative therapies to address unmet medical needs.